Ph 3 Trial of LAE002 (afuresertib) for Breast Cancer Met PFS Primary Endpoint
“We are proud to share that the Phase III clinical trial of LAE002 (afuresertib) for breast cancer has met its primary endpoint. The treatment has brought significant and clinically meaningful improvements to patients, with the top-line results clearly demonstrating best-in-class efficacy and safety profile.” said Dr. Chris Lu, Chairman and CEO of Laekna. “In response to the high unmet medical needs, we are pursuing collaborations with partners to accelerate patient access to this novel therapy in global markets.”
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).